{
  "ticker": "IONS",
  "company_name": "Ionis Pharmaceuticals",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03385239",
      "title": "Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hypertriglyceridemia, Cardiovascular Diseases",
      "start_date": "2018-01-30",
      "completion_date": "2020-02-25",
      "enrollment": 0,
      "sponsor": "Akcea Therapeutics"
    },
    {
      "nct_id": "NCT02300233",
      "title": "The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hypertriglyceridemia",
      "start_date": "2015-02-05",
      "completion_date": "2017-01-24",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00002187",
      "title": "A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis",
      "status": "COMPLETED",
      "phase": "NA",
      "condition": "Cytomegalovirus Retinitis, HIV Infections",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01234025",
      "title": "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Castrate-Resistant Prostate Cancer",
      "start_date": "2010-11",
      "completion_date": "2013-12",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT00048295",
      "title": "Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Crohn's Disease",
      "start_date": "2002-05",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01299298",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteer",
      "start_date": "2011-01",
      "completion_date": "2011-04",
      "enrollment": 0,
      "sponsor": "Kastle Therapeutics, LLC"
    },
    {
      "nct_id": "NCT05355402",
      "title": "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia",
      "start_date": "2022-05-09",
      "completion_date": "2023-12-21",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05079919",
      "title": "A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Severe Hypertriglyceridemia",
      "start_date": "2021-10-25",
      "completion_date": "2025-07-08",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03358030",
      "title": "A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "End-stage Renal Disease (ESRD)",
      "start_date": "2017-12-26",
      "completion_date": "2019-07-10",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02211209",
      "title": "The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Familial Chylomicronemia Syndrome",
      "start_date": "2014-12",
      "completion_date": "2017-03-28",
      "enrollment": 0,
      "sponsor": "Ionis Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 19,
      "PHASE3": 7,
      "NA": 2,
      "PHASE1, PHASE2": 7,
      "PHASE1": 10,
      "": 4,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 41,
      "ACTIVE_NOT_RECRUITING": 5,
      "RECRUITING": 2,
      "WITHDRAWN": 1,
      "TERMINATED": 1
    },
    "active_trials": 7,
    "completed_trials": 41,
    "conditions": [
      "Acromegaly",
      "Advanced Cancers, DLBCL, Lymphoma",
      "Amyloidosis",
      "Angelman Syndrome",
      "Castrate-Resistant Prostate Cancer",
      "Crohn's Disease",
      "Cytomegalovirus Retinitis, HIV Infections",
      "End-stage Renal Disease (ESRD)",
      "Familial Chylomicronemia Syndrome",
      "Familial Partial Lipodystrophy",
      "Healthy Participants",
      "Healthy Subjects, Cystic Fibrosis",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Healthy Volunteers, hATTR Amyloidosis",
      "Hepatic Steatosis",
      "Hepatitis C, Chronic",
      "Hereditary Amyloidosis, Transthyretin-Related",
      "Huntington's Disease",
      "Hypertriglyceridemia",
      "Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia",
      "Hypertriglyceridemia, Cardiovascular Diseases",
      "Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis",
      "Hypertriglyceridemia, Familial Hypercholesterolemia",
      "Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders",
      "Metabolic Diseases, Hyperlipidemias, Metabolic Disorder, Hypercholesterolemia, Dyslipidemias, Lipid Metabolism Disorders",
      "Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome",
      "Multiple System Atrophy",
      "NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic",
      "Non-small Cell Lung Cancer",
      "Paroxysmal Atrial Fibrillation",
      "Primary IgA Nephropathy",
      "Relapsed Multiple Myeloma, Refractory Multiple Myeloma",
      "Severe Hypertriglyceridemia",
      "Steatohepatitis, Nonalcoholic",
      "Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)",
      "Type 2 Diabetes",
      "Type 2 Diabetes Mellitus",
      "Type 2 Diabetes Mellitus, Obese"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:11.938133",
    "search_query": "Ionis Pharmaceuticals",
    "url": "https://clinicaltrials.gov/search?term=Ionis+Pharmaceuticals"
  }
}